Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple Turns 50: From Garage Startup to AI Crossroads 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
BRISBANE, Calif., Dec. 13, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will discuss how Priority Review Vouchers (PRVs) can continue to be effective incentives to help underserved patients during a panel at the U.S. Food and Drug Administration (FDA) / Centers for Medicare and Medicaid Services (CMS) Summit in Washington, D.C., December 14-15, 2016.
Dr. Durrant will also participate in a separate discussion on the significant needs in pediatric drug development.
“Important incentives, such as the PRV system, can support new approaches to bring treatments to many categories of underserved patients, including children,” said Dr. Durrant. “I look forward to engaging regulatory, policy and other stakeholders on how we could further collaborate and share ideas to help overlooked populations.”
Details of the panels follow:
Title: Priority Review Voucher Proliferation: Bane of FDA, Boon for Industry?
Date: Wednesday, December 14, 2016
Time: 3:30 – 4:00 p.m. EST
Participants: Krista Carver, Covington & Burling LLP; Dr. Gayatri Rao, Office of Orphan Products Development, FDA; Dr. Cameron Durrant, KaloBios Pharmaceuticals
Title: Pediatric Drug Development
Date: Thursday, December 15, 2016
Time: 11:15 a.m. – 12:00 p.m. EST
Participants: Dr. Mary Dianne Murphy, Office of Pediatric Therapeutics, FDA (retired); Dr. Stephen Yoo, REGENXBIO; Dr. Cameron Durrant, KaloBios Pharmaceuticals
For more information on the conference, please visit https://lifesciences.knect365.com/fda-cms/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
